Novonix (NVX) grants performance rights, lifting director Michael O’Kronley’s holdings
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Novonix Limited filed a Form 6-K that includes an ASX Appendix 3Y detailing a change in director interests for Michael O’Kronley. The filing records the issue of performance rights to the director following shareholder approval at the AGM held on 15 April 2026.
After this change, Michael O’Kronley holds 9,586,538 performance rights. The notice also confirms that the interests were not traded during a closed period, so no special trading clearance was required.
Positive
- None.
Negative
- None.
Key Figures
Director performance rights holding: 9,586,538 performance rights
AGM approval date: 15 April 2026
Form type: Form 6-K with Appendix 3Y
3 metrics
Director performance rights holding
9,586,538 performance rights
Number of securities held after change for Michael O’Kronley
AGM approval date
15 April 2026
Date of shareholder approval for performance rights issue
Form type
Form 6-K with Appendix 3Y
Change of Director’s Interest Notice for Novonix Limited
Key Terms
performance rights, Appendix 3Y, listing rule 3.19A.2, closed period
4 terms
performance rights financial
"No. of securities held after change | 9,586,538 performance rights"
Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.
Appendix 3Y regulatory
"Appendix 3Y Change of Director’s Interest Notice"
listing rule 3.19A.2 regulatory
"We (the entity) give ASX the following information under listing rule 3.19A.2"
closed period regulatory
"Were the interests in the securities or contracts detailed above traded during a + closed period"
FAQ
What does Novonix (NVX) report in this Form 6-K filing?
Novonix reports a change in director interests via an ASX Appendix 3Y. Director Michael O’Kronley received performance rights that were approved by shareholders at the 15 April 2026 AGM, updating his total performance rights holding and regulatory disclosure.
How many performance rights does Novonix director Michael O’Kronley hold after the change?
After the change, Michael O’Kronley holds 9,586,538 performance rights. This figure reflects the updated position following the issue of new performance rights that were approved at Novonix’s annual general meeting held on 15 April 2026.
What triggered the change in Michael O’Kronley’s interests at Novonix (NVX)?
The change was triggered by the issue of performance rights to Michael O’Kronley. These performance rights were granted following shareholder approval at Novonix’s annual general meeting on 15 April 2026, and are recorded as a direct interest in the Appendix 3Y notice.
Were Novonix (NVX) director securities traded during a closed period?
The filing states the director’s interests were not traded during a closed period. The Appendix 3Y specifically answers “No” to trading during a closed period, so no prior written clearance for trading was required in connection with this change.
Is Michael O’Kronley’s interest in Novonix securities direct or indirect?
The Appendix 3Y identifies Michael O’Kronley’s interest as direct. This means the recorded 9,586,538 performance rights are held directly in his name, rather than through an intermediary entity or trust, clarifying how the director’s holdings are structured.